NASDAQ:ITMR - Itamar Medical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $30.98
  • Forecasted Upside: 2.57 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$30.20
▼ -0.07 (-0.23%)

This chart shows the closing price for ITMR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Itamar Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITMR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITMR

Analyst Price Target is $30.98
▲ +2.57% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Itamar Medical in the last 3 months. The average price target is $30.98, with a high forecast of $33.85 and a low forecast of $29.00. The average price target represents a 2.57% upside from the last price of $30.20.

This chart shows the closing price for ITMR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Itamar Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/20/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$30.00 ➝ $31.00Low
9/15/2021LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$33.85Low
9/14/2021Alliance Global PartnersDowngradeBuy ➝ NeutralLow
9/14/2021CowenDowngradeOutperform ➝ Market Perform$30.00 ➝ $31.00Low
9/14/2021HC WainwrightDowngradeBuy ➝ Neutral$36.00 ➝ $31.00Low
9/13/2021HC WainwrightReiterated RatingBuy ➝ Buy$36.00High
5/20/2021SVB LeerinkLower Price TargetOutperform$33.00 ➝ $30.00High
3/8/2021HC WainwrightBoost Price TargetBuy$30.00 ➝ $36.00Low
3/2/2021Piper SandlerBoost Price TargetOverweight$26.00 ➝ $30.00Low
1/11/2021HC WainwrightReiterated RatingBuy$30.00Medium
12/17/2020HC WainwrightReiterated RatingBuy$30.00Low
11/18/2020HC WainwrightBoost Price TargetBuy$28.00 ➝ $30.00Low
10/14/2020Alliance Global PartnersBoost Price Target$28.00 ➝ $29.00Low
8/17/2020HC WainwrightBoost Price TargetPositive ➝ Buy$21.00 ➝ $28.00High
8/3/2020CowenReiterated RatingBuy$30.00Low
7/28/2020CowenReiterated RatingBuy$30.00Medium
6/18/2020CowenBoost Price TargetOutperform$20.00 ➝ $27.00Low
6/12/2020SVB LeerinkInitiated CoverageOutperform$30.00High
5/28/2020Alliance Global PartnersBoost Price TargetBuy$17.75 ➝ $22.75High
5/28/2020HC WainwrightReiterated RatingBuy$21.00High
5/4/2020HC WainwrightReiterated RatingBuy$21.00High
4/15/2020Alliance Global PartnersLower Price Target$19.50 ➝ $17.75Low
4/13/2020Piper SandlerReiterated RatingBuy$22.00Medium
3/31/2020CowenInitiated CoverageOutperform$20.00Medium
3/23/2020HC WainwrightInitiated CoverageBuy$21.00High
2/5/2020Piper SandlerInitiated CoverageOverweight$22.00Low
8/29/2019Alliance Global PartnersInitiated CoverageBuy$14.00High
8/6/2019LADENBURG THALM/SH SHInitiated CoverageBuyLow
(Data available from 9/23/2016 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 1 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
9/23/2021

Current Sentiment

  • 1 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Itamar Medical logo
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.
Read More

Today's Range

Now: $30.20
Low: $30.18
High: $30.20

50 Day Range

MA: $20.95
Low: $16.67
High: $30.40

52 Week Range

Now: $30.20
Low: $16.36
High: $30.46

Volume

12,761 shs

Average Volume

73,549 shs

Market Capitalization

$486.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Itamar Medical?

The following Wall Street research analysts have issued stock ratings on Itamar Medical in the last year: Alliance Global Partners, Cowen Inc, HC Wainwright, LADENBURG THALM/SH SH, Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ITMR.

What is the current price target for Itamar Medical?

6 Wall Street analysts have set twelve-month price targets for Itamar Medical in the last year. Their average twelve-month price target is $30.98, suggesting a possible upside of 2.6%. LADENBURG THALM/SH SH has the highest price target set, predicting ITMR will reach $33.85 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $29.00 for Itamar Medical in the next year.
View the latest price targets for ITMR.

What is the current consensus analyst rating for Itamar Medical?

Itamar Medical currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ITMR, but not buy more shares or sell existing shares.
View the latest ratings for ITMR.

How do I contact Itamar Medical's investor relations team?

The company's listed phone number is (724) 617-7000. The official website for Itamar Medical is www.itamar-medical.com.